CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The goal of this clinical trial is to learn if the antibody drug HuL001, combined withLenalidomide/Dexamethasone works to treat Multiple Myeloma...
Phase 1, Phase 2
Taipei, Taiwan
doses) of the study medicine (elranatamab) in participants with multiple myeloma that has come back after responding to treatment o ...
Phase 2
Taipei, Taiwan and 51 other locations
This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical ben...
Phase 4
Taipei, Taiwan and 25 other locations
monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Pa...
Phase 3
Taipei, Taiwan and 218 other locations
Unconjugated belantamab antibody in participants with refractory multiple myeloma (RRMM) who have received at least 3 prior therapi...
Phase 1, Phase 2
Taipei, Taiwan and 26 other locations
with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple...
Phase 3
Taipei, Taiwan and 265 other locations
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spon...
Phase 3
Taipei City, Taipei, Taiwan and 164 other locations
This study aims to evaluate alternative dosing regimens of single-agent belantamab mafodotin in participants with relapsed or refractory multiple...
Phase 2
Taipei, Taiwan and 87 other locations
The purpose of this clinical trial is to (1) learn whether the BCMA-CD3 bispecific antibody elranatamab can provide more benefit to people with multiple...
Phase 3
Taipei, Taiwan and 241 other locations
Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells c...
Phase 3
Taipei, Taiwan and 85 other locations
Clinical trials
Research sites
Resources
Legal